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Members of the extended interleukin-1 (IL-1) cytokine family, such as IL-1, IL-18, IL-33, and IL-36, play a
pivotal role in the initiation and amplification of immune responses. However, deregulated production and/
or activation of these cytokines can lead to the development of multiple inflammatory disorders. IL-1 family
members share a broadly similar domain organization and receptor signaling pathways. Another striking sim-
ilarity between IL-1 family members is the requirement for proteolytic processing in order to unlock their full
biological potential. Although much emphasis has been put on the role of caspase-1, another emerging
theme is the involvement of neutrophil- and mast cell-derived proteases in IL-1 family cytokine processing.
Elucidating the regulation of IL-1 family members by proteolytic processing is of great interest for under-
standing inflammation and immunity. Here, we review the identity of the proteases involved in the proteolytic
processing of IL-1 family cytokines and the therapeutic implications in inflammatory disease.Introduction
Interleukins are a group of secreted proteins that function as cy-
tokines to mediate inter-cellular communication during immune
responses. In this review, we concentrate on a particular group
of interleukins, the interleukin (IL)-1 family, which is comprised
of 11 members (Table 1). Some family members are pro-inflam-
matory (IL-1a, IL-1b, IL-18, IL-33, IL-36a, IL-36b, IL-36g),
although IL-37 is thought to play an anti-inflammatory role. Other
members of the extended IL-1 family are anti-inflammatory
(IL-1RA, IL-36RA, IL-38; not discussed in the present review)
by acting as receptor antagonists, thereby setting a threshold
for the activities of the pro-inflammatory family members. IL-1
family cytokines play a central role in mediating immune re-
sponses due to their broad spectrum of biological functions
and the diverse range of cells they target. Therefore, the activity
of these potent cytokines needs to be tightly regulated and this is
achieved in several ways: by controlling the production and
maturation of cytokine precursors, through synthesis of cytokine
receptor antagonists (e.g., IL-1RA and IL-36RA) or decoy recep-
tors, and by intracellular signaling inhibitors. As a testament
to the importance of these cytokines, deregulated activity of
several IL-1 family members is a major cause of inflammatory
and autoimmune disorders. Thus, multiple members of the IL-1
family, as well as their activating proteases, represent attractive
targets for therapeutic manipulation (Dinarello, 2012).
Members of the IL-1 family engage similar receptors (Table 1)
and initiate similar signaling pathways culminating in the expres-
sion of a diverse array of pro-inflammatory cytokines, chemo-
kines, and other factors. For more details on their function in
innate and adaptive immunity, we refer to a recent review (Gar-
landa et al., 2013). IL-1 family members also share a common
structure and are mostly synthesized as precursor proteins
with little or no bioactivity, requiring limited proteolytic process-
ing to unlock their full biological potential (see below). This is an
important regulatory mechanism that maintains potent inflam-matory mediators in an inactive state, thereby minimizing the
potential for erroneous activation of pro-inflammatory signaling.
In the case of IL-1a and IL-1b, proteolytic maturation leads to
conformational changes that convert them from a proteinase
K-sensitive to a proteinase K-insensitive form, likely representing
the transition from conformational states that are incompetent
for receptor binding to states that are competent (Hazuda
et al., 1991). Interestingly, most proteolytic events that activate
IL-1a and IL-1b take place within a limited region at the N termi-
nus (Figure 1; Afonina et al., 2011; Hazuda et al., 1991). This sug-
gests that the N-terminal region within members of the extended
IL-1 family acts as a regulatory switch that keeps these cytokines
inactive, possibly by obscuring the receptor binding site. In this
review we summarize current knowledge on the processing of
several IL-1 cytokine family members by different proteases
and highlight important similarities and differences.
Veteran Members of the IL-1 Family: IL-1a and IL-1b
IL-1 is the prototypic and undoubtedly the most extensively
studied cytokine of the IL-1 family, and it is implicated in a
wide range of inflammatory diseases, including rheumatoid
arthritis, osteoarthritis, gout, periodic fever, and type II diabetes
(Dinarello, 2009). IL-1 affects cells of the innate and adaptive im-
mune system and exerts a wide range of biological activities
including promoting fever, vasodilation, hematopoiesis, lympho-
cyte activation, leukocyte attraction and extravasation, angio-
genesis, and antibody synthesis (Garlanda et al., 2013). This
diverse spectrum of IL-1-mediated activities is shared by two
separately encoded proteins, IL-1a and IL-1b, which surprisingly
have only 26% amino acid homology (Auron et al., 1984; March
et al., 1985). Nevertheless, the two proteins activate the same
cell surface receptor and have a practically identical range of
biological activities. Interestingly, IL-1b but not IL-1a deficiency
has been shown to result in impaired febrile and acute-phase
inflammatory responses in a turpentine-induced model of localImmunity 42, June 16, 2015 ª2015 Elsevier Inc. 991
Table 1. Overview of IL-1 Family Members, Their (Co)-receptors, Inhibitory Ligands plus Receptors, and Main Functions
Cytokine Alternative Name Receptor Co-receptor
Inhibitory Ligands
and Receptors Main Function
IL-1a IL-1F1 IL-1R1 IL-1RAcP IL-1RA, IL-1R2 pro-inflammatory
IL-1b IL-1F2 IL-1R1 IL-1RAcP IL-1RA, IL-1R2 pro-inflammatory
IL-18 IL-1F4 IL-18Ra IL-18Rb IL-18BP pro-inflammatory







IL-36R (IL-1Rrp2) IL-1RAcP IL-36RA pro-inflammatory
IL-37 IL-1F7 IL-18Ra SIGIRR (TIR8, IL-1R8) unknown anti-inflammatory
IL-38 IL-1F10 IL-36R (IL-1Rrp2) – unknown anti-inflammatory
IL-1RA IL-1F3 IL-1R1 – NA IL-1R antagonist
IL-36RA IL-1F5 IL-36R – NA IL-36R antagonist
Abbreviation is as follows: NA, not applicable.
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bility to LPS challenge (Horai et al., 1998; Zheng et al., 1995). On
the other hand, IL-1a has been uniquely implicated in initiating
sterile inflammation in response to dying cells by inducing
neutrophil recruitment, whereas IL-1b has been shown to regu-
late recruitment of macrophages only in a later phase (Rider
et al., 2011). Collectively, these data imply that, despite trig-
gering the same receptor and signaling pathways, IL-1a and
IL-1b are not completely redundant, which might reflect differ-
ences in their localization, expression, and mechanisms of
release in different cell types.
IL-1b
Caspase-1
IL-1b is expressed by hematopoietic cells as a 31-kDa precur-
sor, mostly in response to inflammatory stimuli. However, full-
length pro-IL-1b cannot bind the IL-1R and first needs to be
converted into its mature 17-kDa form (Mosley et al., 1987b).
An IL-1b-converting enzyme was initially described in mono-
cytes and referred to as ICE, which was later re-named
caspase-1 (Kostura et al., 1989; Thornberry et al., 1992).
Caspase-1 is the founding member of the caspase (Cysteine
aspartate-specific protease) family, members of which play
crucial roles in inflammation and immunity (Creagh et al.,
2003; Martin et al., 2012). Caspase-1 processes IL-1b at two
distinct sites, producing a minor 26-kDa product, the function
of which is unknown, and a mature 17-kDa form (Figure 1; Ho-
ward et al., 1991). Mice lacking caspase-1 are reported to be
highly resistant to lipopolysaccharide (LPS)-induced endotoxic
shock and to have decreased serum amounts of IL-1b and other
inflammatory cytokines (Kuida et al., 1995; Li et al., 1995), indi-
cating that caspase-1 is a key protease in IL-1b processing.
However, it has since become clear that, due to the very close
chromosomal location of the Casp1 and Casp11 genes, the
caspase-1-deficient animals used in these early studies in fact
lack both caspase-1 and caspase-11 (caspase-11 is the murine
homolog of human caspase-4 and caspase-5) (Kayagaki
et al., 2011). This raises questions about previous conclusions
based on experiments with these mice. Cells from double
Casp1/Casp11/ mice reconstituted with a Casp11 trans-992 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.gene still do not process and secrete IL-1b (and IL-18) (Kayagaki
et al., 2011), confirming the essential role of caspase-1 in IL-1b
processing. Moreover, in contrast to caspase-1, recombinant
caspase-11 processes IL-1b poorly (Kang et al., 2000).
However, the above-mentioned transgenic mice are sensitive
to LPS-induced lethal septic shock, whereas Casp1/
Casp11/ as well as Casp11/ mice are resistant, arguing
that caspase-11 rather than caspase-1 is the dominant mediator
of LPS-induced lethal shock.
Similar to pro-IL-1b, caspase-1 is also present in cells as an
inactive precursor that needs to be activated via auto-proteo-
lytic processing, adding another level of complexity to the
regulation of IL-1b activity. Caspase-1 activation involves
the formation of the inflammasome, a cytosolic multi-protein
signaling complex that contains caspase-1 and a nucleotide-
binding oligomerization domain-like receptor (NLR) that senses
pathogen-associated molecular patterns (PAMPs) such as
bacterial flagellin or host-derived danger-associated molecular
pattern (DAMP) molecules such as uric acid crystals (Lamkanfi
and Dixit, 2014). Different inflammasomes have been identified
and are defined by the NLR protein that they contain. The
NLRP3 (also known as NALP3) inflammasome is the most
studied and its activation in macrophages can be achieved
with a plethora of PAMPs and DAMPs. Genetic studies indicate
that mutations in NLRP3 are linked with the development of
auto-inflammatory diseases (Aganna et al., 2002; Gattorno
et al., 2007). It is now generally accepted that NLRP3-mediated
activation and release of IL-1b requires two distinct signals: the
first signal can be triggered by various PAMPs after Toll-like
receptor (TLR) activation which induces the NF-kB-dependent
synthesis of NALP3 and pro-IL-1b. The second signal is pro-
vided by the activation of the inflammasome and caspase-1
leading to IL-1b processing (Figure 2). This two-tiered regulation
minimizes the unwanted and potentially detrimental activation
of IL-1b. Importantly, another outcome of caspase-1 activation
is pyroptosis, a form of cell death that is characterized by cell
swelling and membrane rupture (Kayagaki et al., 2011). Cell lysis
allows the release of not only mature IL-1b but also pro-IL-1b,
which thus becomes accessible to proteolysis by extracellular
proteases.
Figure 1. Overview of Proteolytic Events
Known to Regulate the Biological Activity of
Specific IL-1 Family Cytokines
Schematic representation of IL-1a, IL-1b, IL-18,
and IL-33 proteins showing the cleavage sites of
different proteases (NE, neutrophil elastase;
GzmB, granzyme B; CathG, cathepsin G; PR-3,
proteinase-3). Cleavage resulting in increased
biological activity is indicated in green, and
cleavage resulting in decreased biological activity
is indicated in red. Numbering is according to the
primary amino acid sequence of the human pro-
teins. Theminimal active domain in IL-1a and IL-1b
(according to Mosley et al., 1987a) and nuclear
localization signal (NLS) are also indicated.
Immunity
ReviewProteases Derived from Neutrophils and Mast Cells
Joosten et al. (2009) have demonstrated that disease progres-
sion in mice with neutrophil-dominated forms of arthritis is com-
parable in Casp1/ and wild-type mice, suggesting that other
enzymes might have an important role in regulating the activity
of IL-1b. Neutrophils contain a battery of proteases that, upon
release into the extracellular space, promote viral and bacterial
killing, modulate cell proliferation and migration, and regulate
production and activity of cytokines and chemokines (reviewed
in Heutinck et al., 2010). Neutrophil elastase and cathepsin
G have been shown to process IL-1b just a few amino acids
upstream of the caspase-1 cleavage site (Figure 1; Black
et al., 1988; Hazuda et al., 1990). Proteolysis at these sites acti-
vate IL-1b, but the resultant activity is much weaker compared
to activation by caspase-1 (Black et al., 1988; Hazuda et al.,
1990). Similarly, proteinase-3 (PR-3) has been shown to process
and activate IL-1b in vitro, but again less efficiently than
caspase-1 (Coeshott et al., 1999; Li et al., 1995). In addition to
neutrophils, mast cell-derived proteases are also able to acti-
vate IL-1b. In this context, the chymotrypsin-like serine protease
chymase has been shown to convert pro-IL-1b into a biologically
active form that is three amino acids longer at its N terminus
than the mature protein generated by caspase-1 (Figure 1; Miz-
utani et al., 1991). However, the relative activity of mast cell
chymase-processed IL-1b and caspase-1-processed IL-1b
has not been determined.
It is likely that in certain inflammatory conditions characterized
by the release of pro-IL-1b in the extracellular milieu, neutrophil-
and mast cell-derived proteases play an important role in IL-1b
activation. Notably, LPS-treated peritoneal macrophages have
been shown to release pro-IL-1b in response to necrotic stimuli
or mechanical stress (Hogquist et al., 1991), making it accessible
to extracellular proteases. Furthermore, neutrophil- and mast
cell-derived proteasesmight act secondary to caspase-1 activa-
tion and pro-IL-1b release during pyroptosis (Figure 2). In this
way, extracellular proteases would help to enhance and amplify
the initial caspase-1-mediated inflammatory response.ImmunityCaspase-8
Caspase-8 is most well known for its
role in the transmission of pro-apoptotic
signals downstream of death-domain-
containing members of the tumor necro-
sis factor (TNF) receptor family, such
as Fas and TRAIL (van Raam and Salve-sen, 2012). However, accumulating evidence also points to
caspase-8 involvement in a non-canonical, caspase-1-indepen-
dent IL-1b processing pathway (Figure 2). Thus, cellular stress
(inhibition of protein translation, chemotherapeutics, or endo-
plasmic reticulum stress) enables macrophages and dendritic
cells to produce mature IL-1b in response to TLR3 or TLR4
stimulation through a caspase-8-dependent and caspase-1-
independent pathway (Antonopoulos et al., 2013; Maelfait
et al., 2008; Shenderov et al., 2014). Furthermore, stimulation
of dectin-1 (a macrophage-specific C-type lectin receptor) or
Fas receptors, aswell as downregulation of inhibitor of apoptosis
(IAP) proteins, have been independently shown to lead to
caspase-8 activation and caspase-1-independent maturation
of proIL-1b (Bossaller et al., 2012; Gringhuis et al., 2012; Petrella
et al., 2012). It is still unclear whether the role for caspase-8
in pro-IL-b processing reflects a direct effect of caspase-8 on
IL-1b or the caspase-8-mediated activation of another protease
that cleaves IL-1b. However, the observation that recombinant
caspase-8 can cleave pro-IL-1b in vitro at exactly the same
site (Asp116) as caspase-1 makes a direct effect in cells very
likely (Figure 1; Maelfait et al., 2008).
IL-1a
IL-1a is constitutively expressed as a 31-kDa precursor by
epithelial cells, endothelial cells, and keratinocytes. However,
unlike IL-1b, IL-1a exhibits a basal amount of activity in its imma-
ture unprocessed form. IL-1a is released from damaged cells,
and for a long time research on this cytokine was dominated
by the idea that IL-1a does not require proteolytic processing
to exhibit bioactivity. Therefore, the importance of proteolysis
in the regulation of IL-1a activity has been underappreciated.
This paradigmwas fuelled by thework ofMosley and colleagues,
who demonstrated that both full-length and processed IL-1a can
bind the IL-1R and are biologically active (Mosley et al., 1987b).
This view persisted despite a parallel report by the same
group (Mosley et al., 1987a) comparing a panel of N-terminally
truncated IL-1a constructs which indicated that the specific42, June 16, 2015 ª2015 Elsevier Inc. 993
Figure 2. Caspase-1-Dependent and
-Independent IL-1b Processing
Activation of caspase-1 requires two signals.
Signal 1 involves the NF-kB-dependent expres-
sion of NLRP3 and pro-IL-1b, which can be
provided for example by LPS triggering of
TLR4. Signal 2 involves the formation of the
inflammasome and caspase-1 activation that is
triggered upon sensing of specific PAMPs (e.g.,
flagellin) or DAMPs (e.g., uric acid crystals) by
NLRs such as NLRP3. Activated caspase-1 then
processes pro-IL-1b into its mature form. Addi-
tionally, activation of caspase-1 can lead to
pyroptotic cell death, facilitating the release of
both pro- and mature forms of IL-1b into the
extracellular space, where proteases derived
from neutrophils and mast cells can also cleave
and activate pro-IL-1b, thus further amplifying the
inflammatory response. Under certain conditions,
caspase-8 activation in response to dectin-1 or
Fas triggering can mediate caspase-1- and in-
flammasome-independent IL-1b processing.
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fold higher than the unprocessed form. In agreement with the
latter observation, it has been recently demonstrated that cleav-
age of IL-1a by a number of inflammatory proteases, including
elastase, granzyme B, and mast cell chymase, results in a
dramatic increase in IL-1a bioactivity (Afonina et al., 2011).
Thus, similar to IL-1b, the biological activity of IL-1a is also regu-
lated via proteolytic processing.
Calpain
Calpain belongs to a family of proteases involved in cellular
proliferation, differentiation, and apoptosis. Calcium-induced
processing of IL-1a by calpain was first reported by two groups
in the early 1990s (Figure 1; Carruth et al., 1991; Kobayashi et al.,
1990). However, these reports did not explore the functional
consequences of calpain-mediated IL-1a proteolysis. Formal
comparison of the bioactivity of the full-length and calpain-
cleaved forms of IL-1a has shown that proteolysis of IL-1a by
calpain results in a several-fold increase in bioactivity (Afonina
et al., 2011). This can be explained by the different receptor
binding affinities of full-length and mature IL-1a, with the former
having nearly 50-fold lower affinity for IL-1R (Zheng et al., 2013).
Collectively, these data suggest that calpain might play a role as
a regulator of inflammatory processes through converting IL-1a
into its more potent form (Figure 3).
Granzyme B
Granzyme B, a major pro-apoptotic serine protease that is
contained within the lytic granules of cytotoxic lymphocytes
and natural killer (NK) cells, was also found to process and acti-
vate IL-1a (Figure 1; Afonina et al., 2011). IL-1a is readily pro-
cessed by granzyme B both intra- and extracellularly during
NK cell-dependent cytotoxicity (Figure 3). Although the classical
view of cytotoxic granule proteases (granzymes) depicts these
solely as apoptosis-inducing proteases that destroy virus-
infected or transformed cells (Cullen and Martin, 2008), growing994 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.evidence suggests that granzymes also
participate in themodulation of inflamma-
tory responses (Afonina et al., 2010).
Thus, elevated amounts of granzyme B
have been detected in plasma samplesand synovial fluid from patients with rheumatoid arthritis and in
bronchoalveolar lavage from patients with allergic asthma.
Moreover, granzyme B expression is detected in a wide range
of non-cytotoxic cells including keratinocytes, mast cells, and
B cells (reviewed in Afonina et al., 2010), which equips these cells
with the machinery to amplify an immune response via proteo-
lytic processing of inflammatory cytokines. Strikingly, granzyme
B-deficient mice are more resistant to LPS lethality than wild-
type mice, suggesting that granzyme B might also contribute
to immune signaling in response to inflammatory stimuli (Metkar
et al., 2008). Furthermore, when compared to wild-type animals,
mice lacking granzyme B are less effective in generating anti-
body responses to ovalbumin in combination with IL-1a as an
adjuvant, possibly because Gzmb/ mice cannot process
IL-1a to unlock its full biological potential (Afonina et al., 2011).
These data also suggest that adjuvant activity of IL-1a can be
further boosted via proteolytic processing by extracellular prote-
ases present at the inflammatory site, such as granzyme B or
neutrophil-derived proteases.
Proteases Derived from Neutrophils and Mast Cells
Similar to IL-1b, IL-1a is also processed and activated by neutro-
phil-derived proteases and mast cell chymase with an efficiency
that is comparable to its processing by calpain or granzyme B
(Figure 1; Afonina et al., 2011). Persistent inflammatory condi-
tions, such as cystic fibrosis, are characterized by elevated
neutrophil infiltration of tissues, accompanied by increased
amounts of extracellular neutrophil proteases, predominantly
elastase (Hayes et al., 2011). Of note, IL-1a processing activity
is readily detected in the bronchoalveolar lavage fluids from pa-
tients with cystic fibrosis or bronchiectasis (Afonina et al., 2011).
In addition to neutrophils, emerging evidence points to an impor-
tant role for mast cells in pulmonary fibrosis (Andersson et al.,
2011; Overed-Sayer et al., 2013). Importantly, Pseudomonas
aeruginosa, a common respiratory pathogen in cystic fibrosis,
Figure 3. Processing and Biological Functions of IL-1a
Necrotic cells release pro-IL-1a into the extracellular milieu, where it is processed and activated by granzyme B (GzmB), neutrophil elastase (NE), or mast cell
chymase. Intracellularly, pro-IL-1a can be cleaved by calcium-activated calpain or by granzyme B during CTL attack. Although pro-IL-1a is active, cleavage
dramatically enhances its bioactivity. IL-1a subsequently targets a wide range of cells initiating both innate and adaptive immune responses.
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further facilitating neutrophil transendothelial migration (Lin
et al., 2002). IL-1a has also been suggested to initiate sterile
inflammation and mediate early neutrophil recruitment (Chen
et al., 2007; Rider et al., 2011). Collectively, these data suggest
that IL-1-mediated neutrophil recruitment creates an amplifica-
tion loop where neutrophil-derived proteases can further
enhance the inflammatory response via proteolytic activation
of IL-1a (Figure 3).
Although IL-1a and IL-1b bind to the same receptor and exhibit
a similar range of biological effects, IL-1a has some unique prop-
erties that might be affected through proteolysis. First, althoughIL-1a is rarely secreted from cells, a membrane-anchored form
of this cytokine has been reported to induce gene expression
in neighboring cells via a juxtacrine mechanism (Kurt-Jones
et al., 1985, 1987; Sasu et al., 2001). Niki et al. (2004) have
demonstrated that membrane-bound IL-1a contributes to carti-
lage destruction and arthritis development in IL-1a transgenic
mice. Interestingly, mild trypsin or plasmin digestion was shown
to remove IL-1a from the cell surface without destroying its
bioactivity (Matsushima et al., 1986; Niki et al., 2004). These
data suggest that proteolytic processing of membrane IL-1a
by proteases prevalent in the extracellular milieu of an arthritic
joint, such as neutrophil proteases or granzymes, might facilitateImmunity 42, June 16, 2015 ª2015 Elsevier Inc. 995
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actually protect from cartilage destruction. Additionally, IL-1a
possesses an N-terminal nuclear localization signal (NLS) that
directs this cytokine to the nucleus, where it might regulate
the activity of transcription factors in a receptor-independent
manner (Werman et al., 2004; Wessendorf et al., 1993). More-
over, apoptotic cells retain IL-1a within their nuclei, whereas
necrotic cells release IL-1a into the extracellular space (Cohen
et al., 2010). Thus, cleavage of IL-1a by proteases liberated
during necrosis might abolish its nuclear retention through
removal of the NLS, thereby facilitating IL-1a release during
necrosis but retention during apoptosis.
IL-18
IL-18 is primarily a T helper 1 (Th1) cell-oriented cytokine, which
contributes to immune responses by inducing interferon (IFN)-g
production, Th1 cell proliferation, and activation of NK cells
(Okamura et al., 1995; Ushio et al., 1996). However, depending
on the context and interaction with other cytokines, IL-18 can
display various inflammatory activities typical of the other IL-1
family members (Novick et al., 2013). This two-sided nature of
IL-18 makes it a double-edged sword in cancer: whereas Th1
cell-promoting activities of IL-18 ensure anti-tumor immune re-
sponses, the pro-inflammatory functions of IL-18 might facilitate
tumor progression and angiogenesis (Fabbi et al., 2015).
Deletion of Il18 in mice results in obesity, insulin resistance,
atherosclerosis, and hyperglycemia, which together resemble
the features of metabolic syndrome in humans (Netea et al.,
2006). Abnormal IL-18 function is also involved in autoimmune
and inflammatory diseases such as psoriasis and inflammatory
bowel disease (reviewed in Dinarello et al., 2003).
IL-18 is constitutively expressed by most cells in healthy
humans and animals as an intracellular inactive precursor of
24 kDa. Caspase-1 cleaves pro-IL-18 after Asp36 into an active
molecule of 17.2 kDa that is secreted from cells (Figure 1; Ghayur
et al., 1997; Gu et al., 1997). To date, caspase-1 is the only pro-
tease that has been convincingly demonstrated to convert IL-18
into its active form. However, in some cases caspase-1-inde-
pendent processing of IL-18 can be observed. For example,
Fas stimulation results in the release of biologically active IL-18
from caspase-1-deficient murine macrophages (Tsutsui et al.,
1999). This phenomenon is sensitive to caspase inhibitors, point-
ing to the involvement of another member of the caspase family.
It was recently shown that caspase-8-deficient macrophages do
not secrete IL-18 (or IL-1b) in response to Fas stimulation
(Bossaller et al., 2012), so caspase-8 is a likely candidate IL-
18-processing enzyme.
Keratinocytes constitutively express and release pro-IL-18
(Companjen et al., 2000). IL-18 has been implicated in several
inflammatory skin conditions, but its activation mechanism re-
mains unclear. Notably, IL-18 can be processed by mast cell
chymase, which cleaves pro-IL-18 after Phe57, downstream of
the caspase-1 cleavage site (Figure 1; Omoto et al., 2006). How-
ever, the chymase-induced IL-18 cleavage product has only
20% of the activity of mature IL-18 generated by caspase-1.
Notably, the caspase-1-generated IL-18 product is resistant
to subsequent chymase-mediated cleavage, suggesting that
IL-18 undergoes a conformational change upon processing by
caspase-1, which is in line with other findings in the case of996 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.IL-1b (Hazuda et al., 1991). Omoto and colleagues have also re-
ported granzyme B-mediated activation of recombinant IL-18
and increased IL-18 release upon incubation of IL-18-expressing
HaCaT keratinocytes with CD8+ T cells (Akeda et al., 2014;
Omoto et al., 2010). Interestingly, keratinocytes have been
shown to express granzyme B in response to UV radiation,
suggesting a non-cytotoxic function for granzyme B in these
cells (Hernandez-Pigeon et al., 2006, 2007). Additionally, IL-18
processing and release has been reported to be induced
upon co-incubation of IFN-g-primed oral epithelial cells with
neutrophil-derived proteinase-3 and LPS, in the absence of
caspase-1. However, evidence for direct processing of IL-18
by proteinase-3 has not been demonstrated (Sugawara et al.,
2001). Collectively, these data suggest that proteases such as
mast cell chymase and granzyme B released from resident
skin cells can contribute to skin inflammation via activation of
IL-18.
IL-33
IL-33 is a more recently identified member of the IL-1 cytokine
family. Initial studies showed that injection of recombinant
IL-33 into mice leads to splenomegaly, eosinophilia, production
of Th2 cell-associated cytokines (IL-4, IL-5, and IL-13), and
increased serum amounts of IgE and IgA (Schmitz et al., 2005).
IL-33 acts on a wide range of innate immune cells, inducing
the production of Th2 cell-type cytokines and chemokines,
maturation of mast cells, survival and expansion of eosinophils,
and M2-polarization of macrophages (Figure 4; Oboki et al.,
2010). IL-33 has also been shown to activate innate lymphoid
cells group 2 (ILC2) in combination with IL-7 or thymic stromal
lymphopoeitin (TSLP) (Halim et al., 2012). This has a crucial effect
on allergic airway responses ensuring ILC2 expansion and
migration, release of IL-5 and IL-13, followed by eosinophil
recruitment, mucus production, and airway hyper-reactivity.
Moreover, IL-33 and ILC2-derived IL-13 promote activation
and migration of dendritic cells (DCs), which then present anti-
gen to naive CD4+ T cells and mediate their differentiation into
Th2 cells (Besnard et al., 2011; Halim et al., 2014). Thus, IL-33
affects cells of the innate and adaptive immune system and
plays a central role in mediating type 2 inflammatory conditions.
As a result, IL-33 plays a major role in a broad range of diseases,
including rheumatoid arthritis, atherosclerosis, cardiovascular
disease, inflammatory bowel disease, asthma, and chronic
obstructive pulmonary disease (Garlanda et al., 2013; Pei
et al., 2014).
IL-33 engages a structurally similar receptor complex (consist-
ing of ST2 and IL-1RAcP) and largely overlapping signaling path-
ways to other IL-1 family members (Garlanda et al., 2013). It is
expressed as a 31-kDa precursor protein by multiple cell types,
including endothelial cells, keratinocytes, fibroblasts, and leuko-
cytes, either constitutively or in response to different stimuli
(Schmitz et al., 2005). Similar to IL-1a, IL-33 is predominantly
released from cells upon cell damage and acts as an alarmin
that initiates inflammatory responses in the context of cell death
(Cayrol andGirard, 2009; Lu¨thi et al., 2009). IL-33 also possesses
an NLS within its N terminus and is, therefore, normally tethered
in the nucleus. Whether IL-33 has a nuclear function is still
unclear, but it has been proposed that nuclear IL-33 is a
chromatin-associated factor and transcriptional repressor.
Figure 4. Processing and Biological Functions of IL-33
Similar to IL-1a, active pro-IL-33 is released by necrotic cells. On the other hand, caspase-3 and -7 inactivate IL-33 via proteolytic cleavage in apoptotic cells,
thereby silencing its alarmin function. Pro-IL-33 that is released can be processed by extracellular neutrophil- or mast cell-derived proteases, which strongly
enhances its activity. IL-33 targets different cell types and mainly drives Th2-cell-mediated immune responses, characterized by mast cell activation, eosinophil
recruitment, and ILC2 expansion.
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conserved homeodomain-like helix-turn-helix motif within the
IL-33 N-terminal part (Carriere et al., 2007; Roussel et al.,
2008). This domain also associates with the p65 NF-kB subunit,
preventing its binding to DNA and dampening NF-kB-dependent
gene expression (Ali et al., 2011). Alternatively and similar to
IL-1a, nuclear localization of IL-33 has been proposed as a
mechanism to prevent its constitutive release from cells and tolimit its pro-inflammatory potential. This is supported by the
detection of increased amounts of serum IL-33 in mice express-
ing a genetically targeted allele of IL-33 in which the whole
N-terminal chromatin-binding domain (containing also the NLS)
has been replaced by the coding region of the DsRed fluorescent
protein. As a consequence, these animals manifest widespread
non-resolving inflammation and premature death (Bessa et al.,
2014).Immunity 42, June 16, 2015 ª2015 Elsevier Inc. 997
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Initial reports have proposed that IL-33 is activated through
caspase-1-mediated processing (Schmitz et al., 2005). This
view was largely based on artificial truncation of IL-33 at a
proposed caspase-1 processing site, which is, however, not
conserved between the human andmurine forms of this cytokine
(Schmitz et al., 2005). Subsequent studies have demonstrated
that neither recombinant nor endogenous caspase-1 can cleave
IL-33 at concentrations that are sufficient to completely process
IL-1b (Lu¨thi et al., 2009). Instead, it has been reported that IL-33
is cleaved after Asp178 by caspase-3 and -7 in vitro and in
apoptotic cells, leading to its inactivation (Lu¨thi et al., 2009).
Importantly, the latter study also demonstrated that, similar to
IL-1a, IL-33 displays basal activity and does not strictly require
maturation in order to bind and activate the IL-33 receptor.
These findings have been independently confirmed by several
parallel reports (Ali et al., 2010; Cayrol and Girard, 2009; Tala-
bot-Ayer et al., 2009). It is now generally accepted that full-length
IL-33 is biologically active upon release from damaged cells, but
can undergo processing by certain neutrophil-derived proteases
(see below) to amplify its activity. Processing of IL-33 by pro-
apoptotic caspases might represent a mechanism to inactivate
the pro-inflammatory activities of IL-33 during apoptosis (Martin
et al., 2012). This is in contrast to necrotic caspase-independent
cell death, which results in the release of active full-length IL-33
and activation of an inflammatory immune response (Figure 4).
Proteases Derived from Neutrophils and Mast Cells
It has been recently shown that the neutrophil-derived proteases
cathepsin G and elastase cleave full-length IL-33 at different
sites within the N terminus, leading to a 10-fold increase in
IL-33 activity (Figure 1; Lefranc¸ais et al., 2012). Importantly, pro-
cessing of extracellular IL-33 has been detected in bronchoal-
veolar lavage fluid from mice with neutrophil-dominated acute
lung injury, suggesting a physiological role for neutrophil-derived
proteases in the regulation of IL-33 activity (Lefranc¸ais et al.,
2012). Another neutrophil protease, PR-3, also processes
IL-33 at multiple sites (Bae et al., 2012). However, only brief
incubation (5min) of IL-33 with PR-3 produces biologically active
fragments, whereas prolonged exposure results in IL-33 degra-
dation, suggesting that PR-3 might actually dampen the inflam-
matory response by inactivating IL-33 (Bae et al., 2012). Once
again, these data implicate neutrophil-derived proteases in the
amplification of the biological potency of IL-1 family members
(Figure 4).
Recently, mast cell chymase has also been shown to process
IL-33 (Lefranc¸ais et al., 2012; Roy et al., 2014; Waern et al.,
2013). The first two studies suggest that incubation of recombi-
nant IL-33 with mast cell chymase results in its degradation,
but bioactivity of the cleaved IL-33 was not assessed in these
studies. In contrast, Lefrancais and colleagues demonstrated
that mast cell chymase and tryptase cleave IL-33 at the
N terminus and that the corresponding in vitro translated mature
forms of IL-33 exhibit increased ability to activate ILC2 ex vivo.
Further studies are clearly required to resolve these discrep-
ancies. Of interest, mast cell chymase-deficient mice show
elevated airway and inflammatory responses to house dust
mite extracts, suggesting a protective and regulatory role of
mast cell chymase and possibly chymase-mediated IL-33 pro-
cessing during sterile inflammation (Waern et al., 2013).998 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.IL-36
Members of the IL-36 subfamily (IL-36a, IL-36b, and IL-36g) are
encoded by separate genes on the IL-1 locus and share 36%
46% sequence identity (Smith et al., 2000). The IL-36 cytokines
have attracted much interest due to accumulating evidence that
they play an important initiating role in psoriasis (Johnston et al.,
2011; Marrakchi et al., 2011). Mice transgenic for IL-36a
transiently exhibit features of severe skin inflammation that are
exacerbated through deletion of a competitive antagonist of
IL-36 receptor signaling, known as IL-36RA, or through irritation
of the skin with chemical agents (Blumberg et al., 2007).
Moreover, hypomorphic mutations in IL1f5 (the gene encoding
IL-36RA) are linked to generalized pustular psoriasis in humans,
a highly severe and life-threatening form of this disease (Marrak-
chi et al., 2011; Sugiura et al., 2014).
IL-36 cytokines are predominantly expressed in skin and act in
an autocrine fashion on skin-resident fibroblasts and keratino-
cytes. However, high amounts of recombinant unprocessed
IL-36 are required to elicit a biological response in vitro (Towne
et al., 2011). Taking into account that proteolytic processing is
required for activation of other IL-1 family members, it was not
entirely unexpected that artificial removal of N-terminal amino
acids from IL-36 proteins results in a more than 1,000-fold in-
crease in bioactivity (Towne et al., 2011). However, it is not known
how endogenous IL-36 undergoes maturation to its bioactive
form, and the identity of the protease(s) involved remains un-
known. The N termini of IL-36 cytokines lack caspase-cleavage
motifs, making a role for caspases rather unlikely. Considering
the accumulating evidence that IL-36plays a key role in psoriasis,
identifying the IL-36-converting enzyme(s) is of great interest.
IL-37
IL-37 has recently been implicated as an important cytokine
in autoimmunity and inflammation. Elevated amounts of IL-37
have been found in cases of rheumatoid arthritis, Crohn’s
disease, psoriasis, and lupus and during Mycobaterium avium
infection (Clavel et al., 2013). Mouse IL-37 has not been re-
ported, but human IL-37 is active on mouse cells. Five isoforms
(IL-37ae, of which IL-37b is the most studied) are generated
through alternative splicing and have distinct expression profiles
(Clavel et al., 2013). IL-37 expression is induced by TGF-b, as
well as by IL-1b and TLR ligands (Nold et al., 2010). Unlike other
members of the IL-1 family, IL-37 appears to be an anti-inflam-
matory cytokine. Human Il37 transgenic mice show a decreased
response to LPS-induced shock and other inflammatory stimuli
(McNamee et al., 2011; Nold et al., 2010). It has been proposed
that IL-37 acts by dampening LPS- and IL-1b-induced inflam-
matory responses or by enhancing the immunosuppressive
and anti-inflammatory properties of TGF-b (Grimsby et al.,
2004; Nold et al., 2010). IL-37 can bind the IL-18 receptor a chain
and further requires the orphan IL-1 receptor family protein
IL-1R8 (also known as TIR8 or SIGIRR) for its anti-inflammatory
activity (Li et al., 2015; Lunding et al., 2015; Nold-Petry et al.,
2015; Pan et al., 2001). Additionally, IL-37 has been shown to
translocate to the nucleus upon LPS stimulation, where it inhibits
the expression of pro-inflammatory cytokines (Bulau et al., 2014;
Sharma et al., 2008).
Similar to other IL-1 family members, all IL-37 variants lack a
typical signal peptide. Some in vitro evidence suggests that
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cleaving IL-37 after Asp20 (Kumar et al., 2002; Sharma et al.,
2008). However, although overexpressed human IL-37 is pro-
cessed in LPS-stimulated mouse macrophages, cleavage of
IL-37 by endogenous caspase-1 has not been demonstrated
unequivocally (Bulau et al., 2014; Sharma et al., 2008). Moreover,
mutation of the proposed caspase-1 cleavage site has only a
marginal effect on the LPS-induced processing of IL-37, sug-
gesting the involvement of other proteases (Bulau et al., 2014).
Interestingly, mutation of the putative caspase-1 cleavage site
significantly impairs translocation of IL-37 to the nucleus, which
correlates with this mutant’s inability to inhibit LPS-induced IL-6
production upon transfection into bone-marrow-derived macro-
phages (Bulau et al., 2014). Moreover, the anti-inflammatory
function of IL-37 is lost in the absence of Asc or NLRP3, known
components of the caspase-1-activating inflammasome, further
pointing to a possible role for caspase-1 in the nuclear transloca-
tion of IL-37 (Bulau et al., 2014). However, it is important to
stress that all these studies were performed with human IL-37
in mouse cells, which might be prone to artifacts, illustrating
the need for further investigation. To date, only one IL-37 isoform
(IL-37b) has been studied in detail. The above-mentioned puta-
tive caspase-1 cleavage site is conserved among four of the
five isoforms, but it is missing in IL-37a. Compared to the other
isoforms, IL-37a lacks 20 N-terminal amino acids. It will therefore
be interesting to test whether the pro-form of IL-37a is active,
because this could reveal a role for alternative splicing in the
regulation of IL-37 activity.
Therapeutic Implications
Members of the IL-1 family are prominent players in different
inflammatory diseases, such as rheumatoid arthritis, psoriasis,
diabetes, autoinflammatory syndromes, and asthma. Therefore,
products that prevent their biological activity are likely to
have considerable therapeutic utility. Various strategies that
are already in use or under investigation include targeting of
cytokine receptors via soluble receptor antagonists (Anakinra,
a recombinant version of the IL-1 receptor antagonist IL-1RA)
or antagonistic antibodies, neutralization of cytokines via soluble
decoy receptors (the IL-1 inhibitor Rilonacept, also known as
IL-1 Trap, and the soluble IL-33 receptor sST2) or neutralizing
antibodies, and inhibition of cytokine maturation via protease
inhibitors (reviewed in Dinarello et al., 2012). Although Anakinra
has shown much promise in patients with different hereditary
and common autoinflammatory disorders (Dinarello et al.,
2012; Gabay et al., 2011), it is rapidly metabolized by the kidneys
and daily injections of Anakinra are required to sustain its
therapeutic effect, which is accompanied by side effects, such
as pain and discomfort. Currently, there is a clear need for alter-
native strategies.
Because of its essential role in the proteolytic activation of
IL-1b, caspase-1 has been originally considered a very attractive
therapeutic target. However, clinical trials with caspase-1 inhib-
itors have been disappointing. One peptidomimetic caspase-1
inhibitor, pralnacasan (VX-740), has shown much promise in
preclinical studies on mice with collagen-induced arthritis
(Rudolphi et al., 2003). Subsequently, this inhibitor has demon-
strated anti-inflammatory potential in phase II trials in patients
with rheumatoid arthritis, was well tolerated, and caused mini-mum side effects (reviewed in MacKenzie et al., 2010). However,
pralnacasan has been discontinued due to potential liver
toxicity demonstrated in animal trials. Another peptidomimetic
caspase-1 inhibitor, VX-765, has shown much promise in phase
I trials in patients with rheumatoid arthritis and osteoarthritis,
as well as in phase II trials in patients with psoriasis (MacKenzie
et al., 2010). However, no recent developments of VX-765 or
other caspase-1 inhibitors for the treatment of inflammatory dis-
orders have been reported.
The potential clinical relevance of caspase-1-independent
proteolytic maturation of IL-1 family members has been demon-
strated in different mouse models. For example, Guma et al.
(2009) have shown that small molecule inhibitors of elastase or
chymase decrease experimental arthritis in caspase-1-deficient
mice, while an elastase inhibitor reduces IL-1-dependent neutro-
phil infiltration in monosodium urate-induced peritonitis. Like-
wise, high doses of a calpain inhibitor alleviate clinical symptoms
in a mouse model of antibody-induced arthritis, presumably due
to its ability to block the production of mature IL-1a (Yoshifuji
et al., 2005).
For the successful clinical development of IL-1 maturation in-
hibitors, it will be important to discriminate between disease con-
ditions in which IL-1 activation relies on caspase-1 versus those
that are dependent on other proteases, such as neutrophil-
derived enzymes. For example, the presence of mutations in
NLRP3, leading to increased inflammasome activation, that are
associated with the development of CAPS (cryopyrin-associated
periodic syndromes), are indicative for the use of inflammasome
inhibitors in these patients (Aganna et al., 2002; Agostini et al.,
2004). Notably, a new NLRP3 inflammasome-specific inhibitor
MCC950 has recently been shown to inhibit caspase-1 activa-
tion and IL-1b maturation in cells isolated from CAPS patients
in response to LPS ex vivo (Coll et al., 2015). Moreover,
MCC950 is highly effective in amousemodel of CAPS and atten-
uates disease severity in a mouse model of multiple sclerosis.
Importantly, inhibiting caspase-1 activation will also prevent
pyroptosis and release of DAMPs, such as IL-1a and IL-33,
further dampening the immune response. On the other hand,
neutrophil-dominated conditions like arthritis, gout, and pulmo-
nary inflammatory diseases would benefit more from the use of
neutrophil protease inhibitors. However, inhibition of neutrophil
proteases should be considered with great caution, because
these proteases regulate several cytokines and are instrumental
for the host defense against invading pathogens. Also, because
multiple functionally divergent proteases can activate the same
cytokine, inhibiting a single enzyme might not be sufficient to
completely prevent cytokine activation. Therefore, combined
treatment with multiple inhibitors that target different proteases
might be the way to go. Moreover, this might allow the use of
lower doses that only partially inhibit each protease, still allowing
the cleavage of other substrates and therefore reducing the
chance for possible side effects.
An interesting safety latch against IL-1a activation was
recently described by Zheng et al. (2013). In some cells, IL-1a
is constitutively bound to an intracellular IL-1 receptor-2
(IL-1R2), which prevents calpain and other inflammatory
proteases from cleaving and activating IL-1a. Upon initiation of
necrosis, IL-1R2 is degraded and IL-1a becomes available to
proteases (Zheng et al., 2013). It will be worthwhile to investigateImmunity 42, June 16, 2015 ª2015 Elsevier Inc. 999
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mask the protease cleavage region in IL-1a or other IL-1 family
members and prevent their proteolytic activation while avoiding
the inhibition of proteases and their vital functionality in host
defense.
Future Perspectives
Although the proteolytic maturation of several IL-1 family mem-
bers is well characterized, many questions remain. For example,
how does proteolytic cleavage activate these cytokines? Does
this affect protein stability, protein conformation, or interactions
with other proteins or receptors? Available evidence suggests
that processing of specific IL-1 family cytokines can lead to
conformational changes that affect their susceptibility to pro-
teolytic degradation (Hazuda et al., 1991; Lu¨thi et al., 2009).
These changes most likely reflect significant internal structural
reorganization that influence receptor binding but might also
impact on the half-lives of these cytokines. In the case of
IL-1a, it is likely that its long N-terminal pro-peptide blocks re-
ceptor binding and acts as a switch to permit rapid toggling
of IL-1a activity (Afonina et al., 2011). To delineate the role of
the N-termini of all IL-1 family members, it would be interesting
to solve and compare the crystal structures of the full-length
and mature forms. However, due to difficulties in obtaining large
quantities of precursor interleukins, only the crystal structures of
mature or truncated forms are available (Liu et al., 2013; Priestle
et al., 1988). Several protocols describing the purification of
full-length IL-1a have been published in recent years (Afonina
et al., 2011; Zheng et al., 2013), which might help efforts
to determine the crystal structure of full-length IL-1a or other
IL-1 family proteins.
Most members of the IL-1 family can be cleaved by multiple
proteases. However, the relative contribution of each protease
in vivo remains unclear. Processing of a specific IL-1 family
member might be tissue dependent and might vary in different
disease states. Studies on protease-deficient mice have already
contributed important knowledge (Guma et al., 2009; Joosten
et al., 2009). The generation and use of genetically targeted
mice expressing catalytically inactive proteases or uncleavable
mutants of IL-1 family cytokines, combined with specific inflam-
matory disease models, are expected to further increase our
understanding of the biological effects of IL-1 family cytokine
processing and the role of specific proteases. In addition, new
and rapidly developing proteomic approaches might reveal
novel cytokine activating proteases that are more easy to target
therapeutically than those currently known.
IL-1 familymembers have also been implicated in tumor devel-
opment. For example, IL-1 enhances angiogenesis and in this
waymight facilitate tumor invasiveness andmetastasis (Voronov
et al., 2014). IL-18 has a dual role in cancer, promoting anti-
tumor activity of cytotoxic T lymphocytes (CTLs) and NK cells,
while in some conditions enhancing tumor progression, evasion,
and angiogenesis (Fabbi et al., 2015). One could speculate
that granzyme B-mediated activation of IL-1a and IL-18 initially
plays a protective role by stimulating cytotoxic cells, while
neutrophil infiltration in the tumor microenvironment might
promote angiogenesis and tumorigenesis via proteolytic activa-
tion of IL-1 family members by neutrophil-derived proteases.
Thus, it might be worthwhile to explore the idea of targeting1000 Immunity 42, June 16, 2015 ª2015 Elsevier Inc.proteases of tumor-associated neutrophils as a means of anti-
tumor therapy.
A major unresolved question regarding the IL-1 family is the
identity of the proteases that process some of the most
recently identified members of the IL-1 family, i.e., IL-36 and
IL-37. Given their proven role in the regulation of other IL-1
family members, neutrophil-derived or mast cell-derived prote-
ases need to be explored as potential proteases involved in the
processing of IL-36 and IL-37. Because of the clear evidence
that IL-36 is a major player in certain forms of psoriasis, knowl-
edge of the proteases involved in the activation of IL-36 is
extremely interesting for the development of novel therapeutic
approaches.
In conclusion, accumulating evidence obtained in the last few
years indicates that proteolytic processing is a common theme
in the regulation of the activity of IL-1 family cytokines. Although
caspases have received most interest until recently, it is now
clear that other proteases including some well-known neutro-
phil- and mast-cell derived proteases might be equally impor-
tant. The identification of additional proteases involved in the
fine-tuning of IL-1 family cytokines and the elucidation of their
role in inflammation and immunity is likely to keep the scientific
community engaged for many years to come and can be ex-
pected to reveal innovative therapeutic targets.ACKNOWLEDGMENTS
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